Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays

4 Mar 2024

Abstract excerpt

CDK4/6 inhibitors are effective at treating advanced HR+ /HER2- breast cancer, however biomarkers that can predict response are urgently needed. We demonstrate here that previous large-scale screens designed to identify which tumour types or genotypes are most sensitive to CDK4/6 inhibitors have misrepresented the responsive cell lines because of a reliance on metabolic proliferation assays. CDK4/6-inhibited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38438376
DOI: 10.1038/s41523-024-00624-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysPMID 38438376Read ↗

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read ↗

Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell ResponseSemantic proximity Read ↗

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2Semantic proximity Read ↗

Biological specificity of CDK4/6 inhibitors: dose response relationship,in vivosignaling, and composite response signatureSemantic proximity Read ↗

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Semantic proximity Read ↗

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclibSemantic proximity Read ↗

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27Semantic proximity Read ↗

Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell LinesSemantic proximity Read ↗

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilitiesSemantic proximity Read ↗

CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?Semantic proximity Read ↗

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read ↗

CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.